GlassScriptPhysician profile
Darren Malone
NPI 1326263344
$3,023.34
in general payments reported to CMS, 2019-2025
20 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $154 · 2021: $625 · 2022: $574 · 2023: $269 · 2024: $302 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $453.28 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Abbvie INC. | $408.71 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $312.07 | 2019-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $294.71 | 2020-2023 | Flarex |
| Allergan, INC. | $280.81 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $255.90 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $219.02 | 2019-2023 | |
| Baxter Healthcare | $162.86 | 2022 | |
| Bausch & Lomb Americas INC. | $139.17 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $130.99 | 2025 | Xdemvy |
| Rxsight INC | $61.48 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Horizon Therapeutics Plc | $49.98 | 2019-2020 | |
| Oyster Point Pharma, INC. | $47.96 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $39.42 | 2022 | |
| Ocular Therapeutix, INC. | $36.32 | 2024 | Dextenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $36.07 | 2021 | |
| Harrow Eye, LLC | $31.50 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $24.34 | 2020-2021 | |
| Glaukos Corporation | $21.08 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Shire North American Group INC | $17.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.